Denali Therapeutics Inc. (DNLI) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 17 Buy.
The consensus price target is $34.40 (low: $25.00, high: $40.00), representing an upside of 70.6% from the current price $20.16.
Analysts estimate Earnings Per Share (EPS) of $-2.78 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.57 vs est $-2.78 (beat +7.5%). 2025: actual $-2.97 vs est $-2.95 (missed -0.5%). Analyst accuracy: 96%.
DNLI Stock — 12-Month Price Forecast
$34.40
▲ +70.63% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Denali Therapeutics Inc., the average price target is $34.40, with a high forecast of $40.00, and a low forecast of $25.00.
The average price target represents a +70.63% change from the last price of $20.16.
Highest Price Target
$40.00
Average Price Target
$34.40
Lowest Price Target
$25.00
DNLI Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Denali Therapeutics Inc. in the past 3 months
EPS Estimates — DNLI
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.57
vs Est –$2.78
▲ 8.1% off
2025
Actual –$2.97
vs Est –$2.95
▼ 0.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — DNLI
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
